Evidence map›Paper›PMID 35085302›Full record

ArticlePloS one2022

Multi attribute method implementation using a High Resolution Mass Spectrometry platform: From sample preparation to batch analysis.

Sofia B Carvalho, Ricardo A Gomes, Anja Pfenninger, Martina Fischer, Michaela Strotbek, Inês A Isidro, Nihal Tugçu, Patrícia Gomes-Alves

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Sofia B CarvalhoiBET, Instituto de Biologia Experimental e Tecnologica, Oeiras, Portugal.
Ricardo A GomesiBET, Instituto de Biologia Experimental e Tecnologica, Oeiras, Portugal.
Anja PfenningerSanofi R&D, Biologics Development, Industriepark Höchst, Frankfurt am Main, Germany.
Martina FischerSanofi R&D, Biologics Development, Industriepark Höchst, Frankfurt am Main, Germany.
Michaela StrotbekSanofi R&D, Biologics Development, Industriepark Höchst, Frankfurt am Main, Germany.
Inês A IsidroiBET, Instituto de Biologia Experimental e Tecnologica, Oeiras, Portugal.
Nihal TugçuMammalian Platform, Global CMC Development, Sanofi, Framingham, MA, United States of America.
Patrícia Gomes-AlvesiBET, Instituto de Biologia Experimental e Tecnologica, Oeiras, Portugal.ORCID 0000-0001-7245-6785
Instituto de Biologia Experimental e Tecnológica · PTSanofi (Germany) · DESanofi (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quality control of biopharmaceuticals such as monoclonal antibodies (mAbs) has been evolving and becoming more challenging as the requirements of the regulatory agencies increase due to the demanding complexity of products under evaluation. Mass Spectrometry (MS)-based methods such as the multi-attribute method (MAM) are being explored to achieve a deeper understanding of the attributes critical for the safety, efficacy, and quality of these products. MAM uses high mass accuracy/high-resolution MS data that enables the direct and simultaneous monitoring of relevant product quality attributes (PQAs, in particular, chemical modifications) in a single workflow, replacing several orthogonal methods, reducing time and costs associated with these assays. Here we describe a MAM implementation process using a QTOF high resolution platform. Method implementation was accomplished using NIST (National Institute for Standards and Technology) mAb reference material and an in-process mAb sample. PQAs as glycosylation profiles, methionine oxidation, tryptophan dioxidation, asparagine deamidation, pyro-Glu at N-terminal and glycation were monitored. Focusing on applications that require batch analysis and high-throughput, sample preparation and LC-MS parameters troubleshooting are discussed. This MAM workflow was successfully explored as reference analytical tool for comprehensive characterization of a downstream processing (DSP) polishing platform and for a comparability study following technology transfer between different laboratories.

Indexed as

Antibodies, MonoclonalBiological ProductsChromatography, LiquidMass SpectrometryQuality ControlResearch DesignTrypsinWorkflowAntibodies, MonoclonalBiological ProductsTrypsin

Identifiers

PMID35085302
PMCPMC8794205
OpenAlexW4210296462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.